Edition:
United Kingdom

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,119.00GBp
18 Aug 2017
Change (% chg)

-71.00 (-5.97%)
Prev Close
1,190.00
Open
1,183.00
Day's High
1,188.00
Day's Low
1,115.00
Volume
1,887,193
Avg. Vol
885,172
52-wk High
2,346.00
52-wk Low
1,101.00

HIK.L

Chart for HIK.L

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products... (more)

Overall

Beta: 1.40
Market Cap(Mil.): £2,691.18
Shares Outstanding(Mil.): 240.65
Dividend: 8.50
Yield (%): --

Financials

  HIK.L Industry Sector
P/E (TTM): 20.85 30.61 31.81
EPS (TTM): 0.54 -- --
ROI: 4.67 14.48 14.02
ROE: 6.88 15.57 15.34

Drugmaker Hikma trims sales forecasts, shares fall

Hikma Pharmaceuticals Plc on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low.

17 Aug 2017

Drugmaker Hikma trims sales forecasts, shares fall

Hikma Pharmaceuticals Plc on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low.

17 Aug 2017

UPDATE 2-Drugmaker Hikma trims sales forecasts, shares fall

Aug 17 Hikma Pharmaceuticals Plc on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low.

17 Aug 2017

BRIEF-Hikma says focused on cost reduction across generics business

* HIKMA PHARMACEUTICALS PLC SAYS COMPANY IS FOCUSED ON COST REDUCTION ACROSS ALL AREAS OF GENERICS BUSINESS - COMPANY EXEC

17 Aug 2017

Drugmaker Hikma expects 2017 revenue at the lower end of guidance

Aug 17 Hikma Pharmaceuticals Plc said on Thursday it expected 2017 revenue at the lower end of its guidance, after increased competition in the generics business hit prices and volumes.

17 Aug 2017

BRIEF-Drugmaker Hikma lowers full-year revenue guidance

* INTERIM DIVIDEND OF 11.0 CENTS PER SHARE, IN LINE WITH INTERIM DIVIDEND FOR H1 2016

17 Aug 2017

BRIEF-Hikma inks Middle East, North Africa licensing deal with Takeda

* HIKMA ANNOUNCES NEW LICENSING AGREEMENT WITH TAKEDA FOR PRODUCTS IN MIDDLE EAST AND NORTH AFRICA

17 Aug 2017

BRIEF-Hikma signs license, supply agreement for Octaplex‍​

* Hikma signs an exclusive license and supply agreement with Octapharma for Octaplex‍​

31 May 2017

Hikma cuts revenue forecast on generic Advair delay; shares sink

Hikma Pharmaceuticals Plc lowered its full-year revenue forecast on Friday to reflect a delay in the launch of its generic asthma drug amid pricing pressures in the United States, sending its shares down to a three-year low.

19 May 2017

UPDATE 2-Hikma cuts revenue forecast on generic Advair delay; shares sink

May 19 Hikma Pharmaceuticals Plc lowered its full-year revenue forecast on Friday to reflect a delay in the launch of its generic asthma drug amid pricing pressures in the United States, sending its shares down to a three-year low.

19 May 2017

Earnings vs. Estimates